Psychedelic Stock Review | Ultimate News Source for Psychedelic Investors

Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine LIVE QUOTE

View Post

Silo Pharma (SILO) $3.36 Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation

Featured Editor | Curator - November 11, 2022

View Post ENGLEWOOD CLIFFS, NJ, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage...

View Post

Stressed Wall Street Execs Flock to Ketamine Therapy Sessions (NY Post)

CLINICS Editor | Curator - October 23, 2022

Therapy’s a trip for these Wall Street executives. Wealthy stock traders are flocking to a Manhattan-based ketamine therapy practice that doles out...

View Post

Silo Pharma (SILO) Attends Dawson James Conference.

CLINICAL TRIALS Editor | Curator - October 22, 2022

We watched an excellent presentation from management at the Dawson conference and starting our due diligence now....

View Post

‘Magic Mushroom’ Psychedelic may Help Heavy Drinkers Quit (AP News)

PSYCH NEWS Editor | Curator - August 25, 2022

Psychedelic Drug Helped People with Alcohol use Disorder Reduce Drinking, Study Shows (Today) Psilocybin,...

View Post

Stan Grof, Psychedelic’s Elder Statesman.

INTERVIEW Editor | Curator - August 15, 2022

Stan Grof — Lessons from ~4,500 LSD Sessions and Beyond https://youtu.be/3mdYUmvTeig PLAYLIST

View Post

PharmaTher (PHRM, PHRRF) $0.10 Gets $3.80 Price Target From H.C. Wainwright – 37 Times (3,700%) Higher.

RESEARCH Editor | Curator - July 15, 2022

Thus, to us, the key potential positive events that could lead to a rerating in PHRM.CN shares include publication of the Phase...

View Post

Ehave, Inc. Announces its KetaDASH Mobile Unit Delivered to Miami Beach.

CLIENT Editor | Curator - June 22, 2022

MIAMI, June 03, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced...

View Post

Australian Icannex (IHL:ASX) Headed to NASDAQ?

Featured Editor | Curator - February 10, 2022

Incannex completes Phase 2 trial for its cannabinoid drug for sleep apnea, flags Nasdaq listing in 2022

View Post

Testimonial: The Ibogaine Clinic, Playa Del Carmen

TESTIMONIALS Editor | Curator - December 25, 2021

VIDEO TESTIMONIALS https://youtu.be/hrrLoxuR2oo VISIT WEBSITE

View Post

12 3...8 Page 1 of 8

KetaDash

Ketamine at Home Treatments

RESEARCH

PSYCHECEUTICAL TO CONDUCT THE FIRST EVER PHASE I AND II CLINICAL TRIALS OF A NOVEL KETAMINE TOPICAL CREAM TO TREAT PTSD

The Kahner Global Cannabis & Psychedelics Investment Summit.

Awakn Life Sciences (AWKNF) $0.30 Announces Signing of Lease for Second Clinic in Norway.

Silo Pharma (SILO) Issues Letter to Shareholders

Silo Pharma (SILO) $3.36 Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation

Stressed Wall Street Execs Flock to Ketamine Therapy Sessions (NY Post)

Silo Pharma (SILO) Attends Dawson James Conference.

Subscribe for Free!

2021 Psychedelic Investor Guide.

2023 Psychedelic Investor Conference

ALL PSYCHEDELIC AND PSYCHEDELIC STOCK NEWS

KetaDash

Most Popular

LARGE CAP PSYCHEDELIC STOCKS

Australian Icannex (IHL:ASX) Headed to NASDAQ?

Small Pharma (DMT, DMTTF) $0.46 a Small and Extremely Interesting Psychedelic Company.

Interview: Great Interview With Cybin (CYBN) CEO Doug Drysdale.

PSYCHEDELIC FUNDS AND ETFS

AdvisorShares Psychedelics ETF (PSIL)

Novamind (NVMDF) Announces Inclusion in NYSE Listed AdvisorShares Psychedelics ETF (PSIL)

Horizons Psychedelic Index ETF.